-
Upgrades
- Bayer (BAYRY) upgraded to Buy from Hold at Kepler Cheuvreux
- First Solar (FSLR) upgraded to Buy from Hold at Jefferies, tgt $192
- J.M. Smucker (SJM) upgraded to Buy from Hold at Jefferies, tgt $115
- Urban Outfitters (URBN) upgraded to Outperform from Neutral at Robert W. Baird, tgt $90
- Bayer (BAYRY) upgraded to Buy from Hold at Kepler Cheuvreux
-
Downgrades
- Arista Networks (ANET) downgraded to Neutral from Outperform at BNP Paribas Exane, tgt $106
- Bill (BILL) downgraded to Equal Weight from Overweight at Morgan Stanley, tgt $55
- Etsy (ETSY) downgraded to Sell from Neutral at Arete, tgt $43
- Ingram Micro (INGM) downgraded to Equal Weight from Overweight at Morgan Stanley, tgt $22
- Sunrun (RUN) downgraded to Underperform from Hold at Jefferies, tgt $5
- UnitedHealth (UNH) downgraded to Neutral from Outperform at Robert W. Baird, tgt $312
- Arista Networks (ANET) downgraded to Neutral from Outperform at BNP Paribas Exane, tgt $106
-
Others
- American Superconductor (AMSC) initiated with a Buy at Clear Street, tgt $44
- Artiva Biotherapeutics (ARTV) assumed with a Buy at H.C. Wainwright, tgt $12
- Avidity Biosciences (RNA) initiated with a Strong Buy at Raymond James, tgt $65
- Coinbase (COIN) initiated with an Outperform at William Blair
- Core Natural Resources (CNR) initiated with a Buy at UBS, tgt $80
- Disc Medicine (IRON) resumed with a Strong Buy at Raymond James, tgt $89
- DoorDash (DASH) initiated with a Hold at Stifel, tgt $198
- Dyne Therapeutics (DYN) assumed with an Outperform at Raymond James, tgt $37
- Gold Royalty (GROY) initiated with a Buy at Canaccord, tgt $3
- Mineralys Therapeutics (MLYS) initiated with a Hold at Jefferies, tgt $15
- Pharvaris (PHVS) initiated with a Buy at Guggenheim, tgt $32
- Summit Therapeutics (SMMT) initiated with an Underperform at Leerink, tgt $12
- TD Synnex (SNX) initiated with an Overweight at Morgan Stanley, tgt $145
- Tectonic Therapeutic (TECX) resumed with an Outperform at Raymond James, tgt $76
- Travere Therapeutics (TVTX) assumed with a Buy at H.C. Wainwright, tgt $30
- Uber (UBER) initiated with a Buy at Stifel, tgt $110
- Wave Life Sciences (WVE) assumed with an Outperform at Raymond James, tgt $14
- American Superconductor (AMSC) initiated with a Buy at Clear Street, tgt $44
In reaction to earnings/guidance:
- GTLB -11.9%, CHWY -7.8%, GME -4.3%, VSCO -0.5%
- CABA -17.4% (announces new rese-cel safety and efficacy data in patients with myositis, lupus and scleroderma to be presented at the EULAR 2025 Congress; announces proposed public offering of securities)
- AMSC -16.1% (stock offering)
- KRT -9.2% (prices secondary offering of 1.5 mln shares of common stock at $27.00 per share)
- CLF -6.9% (US, Mexico nearing deal on steel duties, according to Bloomberg)
- IREN -3.5% (prices upsized offering of $500 million of 3.50% convertible senior notes due 2029)
- NUE -3.4% (US, Mexico nearing deal on steel duties, according to Bloomberg)
- ETSY -3.2% (proposes offering of $650 mln of convertible senior notes due 2030)
- JYNT -3% (names new CFO)
- BY -2.9% (prices secondary offering of 4,282,210 shares of common stock at $24.75 per share and concurrent share repurchase)
- BTSG -2.6% (prices secondary offering of 14.0 mln shares of common stock at $21.75 per share)
- KEN -2.4% (subsidiary OPC Energy announced updates on its offering of new shares)
- GGAL -2.3% (prices secondary offering by HSBC Bank of 11,721,449 ADSs at $54.25 per ADS)
- ADNT -1.9% (following investor presentation)
- BRO -1.5% (prices offering of 39,215,686 shares of its common stock at $102.00 per share)
- STLD -1.4% (US, Mexico nearing deal on steel duties, according to Bloomberg)
In reaction to earnings/guidance:
- SFIX +12.5%, SAIL +10.6%, PLAY +7.1%
- XNET +8.7% (investee company completes IPO on Shanghai Stock Exchange STAR Market)
- NMG +7.6% (firming up its project debt financing structure with the intended participation of syndicate institutional funds and export credit agencies for over US$1 billion toward the Company's Phase-2 Matawinie Mine and Bécancour Battery Material Plant)
- SSTK +7.1% (GETY SSTK merger proposal approved by shareholders)
- GETY +5.9% (GETY SSTK merger proposal approved by shareholders)
- CLDX +4.6% (announces presentations of Barzolvolimab Phase 2 Data)
- CXW +2.7% (to acquire the Farmville Detention Center)
- MXCT +2.6% (MaxCyte and Ori Biotech successfully integrate their ExPERT and IRO platforms to improve the yield of gene-edited T cells and shorten manufacturing timelines)
- CRVS +2.3% (presents soquelitinib preclinical data highlighting potential of ITK inhibition to treat systemic sclerosis at EULAR 2025 Congress)
- VTS +2.1% (CEO bought 10000 shares)
- MT +1.8% (US, Mexico nearing deal on steel duties, according to Bloomberg)
- IPX +1.8% (has received the first task order, valued at $1.3 million, from the U.S. Army)
- DNUT +1.7% (sells remaining stake in Insomnia Cookies)
- AB +1.5% (reports May AUM)
- INMB +1.5% (presents data from study)
- NVAX +1% (Co's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial)
-
Gapping up:
- SFIX +12.9%, XNET +10.1%, GETY +8.3%, PLAY +7.8%, SSTK +6.9%, CLDX +4.6%, VTS +2.8%, CXW +2.7%, DNUT +2.7%, MXCT +2.6%, BTSG +2.1%, MT +2.1%, IPX +1.8%, AB +1.5%, INMB +1%
-
Gapping down:
- CABA -19.6%, AMSC -15%, GTLB -12%, KRT -9.4%, CLF -6.9%, GME -4.7%, IREN -4.5%, BY -3.8%, JYNT -3%, NUE -2.8%, STLD -2.8%, FUFU -2.8%, KEN -2.4%, GGAL -2.3%, HP -1.3%, BRO -1%
* Capricorn Energy Raised to Neutral at Stifel; PT 253 pence
>>> Down
* HKFoods Cut to Reduce at Inderes; PT 1.50 euros
>>> Initiation
* Stora Enso ADRs Rated New Neutral at BNPP Exane; PT $10.40
>>> Call
* Uber Rated New Buy at Stifel on Growth View; DoorDash Rated Hold
* Capricorn Energy Raised to Neutral at Stifel; PT 253 pence
>>> Down
* HKFoods Cut to Reduce at Inderes; PT 1.50 euros
>>> Initiation
* Stora Enso ADRs Rated New Neutral at BNPP Exane; PT $10.40
>>> Call
* Uber Rated New Buy at Stifel on Growth View; DoorDash Rated Hold
Macro :
- No Changes in Composition of AEX Index, Euronext Says
Keep an eye on :
- APOTEA SS : Apotea Sverige Holders Offer Up to 8.8m Shares, Apotea Sverige Offering by Holders Prices at SEK92/Share
All,
Update on the ALHG FP's holding following the AMF disclosure that Financière Agache did exercise its MMB FP's transfer rights.
1/ Conclusion
On June 10th, VIV FP disclosed that it acquired on June 05th, Financière Agache's position in MMB FP (11.2m shares, AMF's filing attached).
Financière Agache did ultimately exercise its MMB's transfer rights (deadline was June 15th).
The recent article suggesting BOL FP acquired Financière Agache's position in MMB FP was wrong.
As a result, VIV FP now owns 13.2% of MMB FP and could own up to 13.8% if the remaining 879m MMB FP transfer rights are exercised.
VIV FP's MMB stake increase has limited impact on its holding discount to NAV which is currently 43.5%.
We believe MMB FP could be worth up to €28.2 per share.
However, Financière Agache's decision to exercise its transfer rights do not play in favor of our opinion on MMB FP's valuation.
2/ MMB FP's updated shareholding structure
MMB FP's shareholding structure is now as per the below:
![]()
3/ Potential next step, ALHG/MMB structure collapse
As suggested in our previous note, BOL FP might decide, at some point, to collapse MMB FP and ALHG FP.
Making a basic assumption of an exchange ratio set at no premium to MMB FP's current price and using ALHG FP's current price as a reference, this would Imply an exchange ratio of 11.8 ALHG share per MMB share.
BOL FP would then control 24.2% of ALHG FP's capital (directly and indirectly through VIV FP).
![]()
4/ ALHG FP's SOP
Using MMB's current price of €20.1, ALHG is currently trading at a 21.4% discount to its NAV.
![]()
However, MMB's current price is not properly reflecting the true value of its assets and it seems as if MMB FP is currently undervalued.
Valuing the Publishing business at 11.2x EV/EBIT 25E and the Travel Retail business at 8.7x EV/EBIT 25E, MMB FP could be worth €28.2 per share or a 28.8% discount to its adjusted NAV.
![]()
Applying our MMB valuation, ALHG would thus be trading at a 42.1% discount to its “see-through” NAV.
5/ VIV FP's updated SOP
VIV FP is currently trading at a 43.5% discount to its NAV.
![]()
David Darmouni
Equity Sales
Makor Securities London Ltd. | Makor Group
6th Floor, 30 Panton Street, London, SW1Y 4AJ
![]()
This message has been sent by Makor Securities, London, part of Makor Group, which is authorised and regulated by the FCA (625054). This message is for professional clients and eligible counterparties only, not intended for "retail clients". The information contained in this message is confidential and is for the exclusive use of the intended recipient. If you receive this message in error please inform us and delete all copies of it. The information is not intended as an offer or solicitation to buy or sell any financial instrument. All comments and statements are to be considered the opinions of the author not the Company and are not intended to be relied upon. We cannot guarantee that this message or any attachments are virus free and accept no liability for any viruses or the consequences thereof. v20230124
- Novo (NOV TH) +1.3%
- Legal & General (LGI TH) +1.2%
- Bayer (BAYN TH) +1%
- Bayer Raised to Buy at HSBC; PT 32 euros
- Rolls-Royce (RRU TH) +1%
- Leonardo (FMNB TH) -1.3%
- Deutsche Boerse (DB1 TH) -1.4%
- Safran (SEJ1 TH) -1.4%
- Thales (CSF TH) -1.7%
- Brenntag (BNR TH) -1.9%
- Talanx (TLX TH) -2%
- Rheinmetall (RHM TH) -2.5%
- Inditex (IXD1 TH) -3.5%
- *INDITEX 1Q EBIT EU1.64B, EST. EU1.65B
- Hensoldt (HAG TH) -4.3%
- RENK Group (R3NK TH) -5.7%